Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 27, 2026, 9:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Type II Obese Diabetic Clear all
Completed Phase 2 Interventional Results available

A 12-WEEK TITRATE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACODYNAMICS OF PF-06882961 IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND IN NON-DIABETIC ADULTS WITH OBESITY

NCT04617275
View directory record Official record
Conditions
Diabetes, Obesity
Interventions
PF-06882961, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
38
States / cities
Phoenix, Arizona • Searcy, Arkansas • Montclair, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Jun 27, 2026, 9:16 AM EDT
Completed No phase listed Observational

Nutritional Regulation of Wound Inflammation: Part III

NCT02332993
View directory record Official record
Conditions
Negative Pressure Therapy, Wound, Open Wound, Type II Obese Diabetic, Type II Non-Obese Diabetic
Interventions
FPP
Dietary Supplement
Lead sponsor
Ohio State University
Other
Eligibility
30 Years to 30 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Jun 27, 2026, 9:16 AM EDT
Completed Not applicable Interventional Results available

The Influence of Physical Activity on the Gut Microbiome of Pre-Diabetic Adults

NCT04931836
View directory record Official record
Conditions
Obesity, Overweight, Overweight and Obesity, PreDiabetes, Type 2 Diabetes, Type 2 Diabetes Mellitus, Type 2 Diabetes Mellitus in Obese
Interventions
Physical Activity Intervention
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
30 Years to 64 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Jun 27, 2026, 9:16 AM EDT
Completed Phase 4 Interventional

SMOOTH - Blood Pressure Control in Diabetic/Obese Patients

NCT00239538
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus, Type 2
Interventions
telmisartan combined with hydrochlorothiazide (80/12.5 mg), valsartan combined with hydrochlorothiazide (160/12.5mg)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
30 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
60
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Jun 27, 2026, 9:16 AM EDT
Completed Phase 1 Interventional

A Single Dose, Tolerance and Pharmacokinetic Study in Obese or Overweight Type 2 Diabetic Volunteers

NCT00606112
View directory record Official record
Conditions
Diabetes Mellitus, Obesity
Interventions
Trodusquemine (MSI-1436)
Drug
Lead sponsor
Genaera Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2009 · Synced Jun 27, 2026, 9:16 AM EDT
Completed No phase listed Observational

Endotoxin and Intestinal Flora Before and After Gastric Bypass or Banding in Diabetics

NCT00960765
View directory record Official record
Conditions
Obesity, Morbid, Diabetes Mellitus, Type 2, Gastric Bypass
Interventions
Not listed
Lead sponsor
CPL Associates
Other
Eligibility
18 Years to 95 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Buffalo, New York • Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2016 · Synced Jun 27, 2026, 9:16 AM EDT
Completed Not applicable Interventional

Effect of Discontinuation of Sugar Sweetened Beverages

NCT00585897
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
discontinuation of sugar sweetened beverages
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 13, 2015 · Synced Jun 27, 2026, 9:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes

NCT04880291
View directory record Official record
Conditions
Kidney Diseases, Diabetic Nephropathies, Diabetes Complications, Diabetes Mellitus, Endocrine System Diseases
Interventions
GFB-024, Placebo
Drug
Lead sponsor
Goldfinch Bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Jun 27, 2026, 9:16 AM EDT
Completed Phase 1 Interventional Results available

A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide

NCT04407234
View directory record Official record
Conditions
Overweight, Obesity, Diabetes Mellitus, Type 2
Interventions
Tirzepatide, Acetaminophen
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Jan 7, 2024 · Synced Jun 27, 2026, 9:16 AM EDT
Completed Not applicable Interventional Results available

The Effect of Januvia (Sitagliptin) on Oxidative Stress in Obese Type 2 Diabetic Subjects

NCT00659711
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Januvia (Sitagliptin) 100 mg, Placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
20 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Jun 27, 2026, 9:16 AM EDT
Completed Phase 1 Interventional

A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension Period

NCT03414736
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
SAR425899
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Saint Paul, Minnesota • Knoxville, Tennessee • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Jun 27, 2026, 9:16 AM EDT
Completed Phase 3 Interventional Results available

24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years

NCT00976937
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Lixisenatide (AVE0010), Lixisenatide Placebo, Pen auto-injector, Sitagliptin, Sitagliptin Placebo, Metformin
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 49 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
21
States / cities
Montgomery, Alabama • Muscle Shoals, Alabama • Mesa, Arizona + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2016 · Synced Jun 27, 2026, 9:16 AM EDT
Active, not recruiting Not applicable Interventional

The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes

NCT01047735
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity
Interventions
Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
Procedure · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
25 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jun 27, 2026, 9:16 AM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Molecular and Clinical Profile of Diabetes Mellitus and Its Complications

NCT01105858
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetic Nephropathy, Obesity
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 99 Years
Enrollment
2,310 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Jun 27, 2026, 9:16 AM EDT
Completed Not applicable Interventional Results available

Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles

NCT01231984
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
4 mm x 32G Pen Needle, 8mm x 31G Pen Needle, 12.7mm x 29G Pen Needle
Device
Lead sponsor
Becton, Dickinson and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Escondido, California • Atlanta, Georgia • Springfield, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jun 27, 2026, 9:16 AM EDT
Completed Not applicable Interventional

Lifestyle Management of CKD in Obese Diabetic Patients

NCT02276742
View directory record Official record
Conditions
Obesity, Type 2 Diabetes, Chronic Kidney Disease (CKD)
Interventions
Social Cognitive Theory, Monitoring
Behavioral · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
40 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Jun 27, 2026, 9:16 AM EDT
Completed Phase 4 Interventional Results available

Testosterone Replacement in Men With Diabetes and Obesity

NCT01127659
View directory record Official record
Conditions
Hypogonadism
Interventions
testosterone, placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
30 Years to 65 Years · Male only
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Jun 27, 2026, 9:16 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Efficacy of mHealth Apps for Health in a Low-income, Type II Diabetic, Hispanic Population

NCT05279729
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Obesity
Interventions
Mobile health application
Other
Lead sponsor
San Diego State University
Other
Eligibility
18 Years to 64 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2025 · Synced Jun 27, 2026, 9:16 AM EDT
Terminated Phase 3 Interventional Results available

Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy

NCT04741074
View directory record Official record
Conditions
CKD, Diabetic Kidney Disease, Type 2 Diabetes Mellitus in Obese, Obesity, Severe Obesity
Interventions
Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution, Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution
Drug
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Danville, Pennsylvania • Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Jun 27, 2026, 9:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Walking and Heating on Vascular Function in Diabetic Patients

NCT03203694
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity
Interventions
Walking: Intervention arm in diabetics, Walking: No intervention in diabetics, Walking: Healthy cohort as reference controls, Lower body heating: Intervention arm in healthy subjects, Lower body heating: Intervention arm in diabetics, Lower body heating: Healthy cohort as reference controls
Behavioral · Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 65 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Jun 27, 2026, 9:16 AM EDT
Completed Phase 2 Interventional Results available

Study of VI-0521 Compared to Placebo in the Glycemic Management of Obese Diabetics

NCT00486291
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
VI-0521, Placebo
Drug
Lead sponsor
VIVUS LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
9
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2012 · Synced Jun 27, 2026, 9:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Long Term Free Living Study With Modified Foods and Type 2 Diabetics

NCT00198913
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity
Interventions
lower fat food supplied and education, gift cards for grocery foods and written education
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2003
U.S. locations
1
States / cities
Lutherville, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 19, 2005 · Synced Jun 27, 2026, 9:16 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

UCSD Take Charge Study

NCT01345500
View directory record Official record
Conditions
Overweight, Obese, Obesity, Diabetic, Type 2 Diabetes
Interventions
Higher Carbohydrate, Lower Fat Diet, Lower carbohydrate, Higher fat diet, Individualized Counseling
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
La Jolla, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 13, 2013 · Synced Jun 27, 2026, 9:16 AM EDT
Completed No phase listed Observational

Impact of Plasma Soluble Prorenin Receptor in Obese and Type 2 Diabetic Patients

NCT03643783
View directory record Official record
Conditions
Obesity, Type2 Diabetes, Bariatric Surgery Candidate
Interventions
Not listed
Lead sponsor
Tulane University
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 28, 2021 · Synced Jun 27, 2026, 9:16 AM EDT